Clinical trial
Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer
NCT00330161 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00330161 |
|---|---|
| Title | Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer |
| Official title | Phase II Evaluation of Suberoylanilide Hydroxamic Acid (NSC 701852) in Patients With Advanced Prostate Cancer That Has Progressed on One Prior Chemotherapy |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Prostate Cancer, Stage IV Prostate Cancer |
| Intervention type | Drug, Other |
| Interventions | vorinostat, laboratory biomarker analysis |
| Enrollment | 29 |
| Start date | Mar 1, 2006 |
| Primary completion | Sep 1, 2009 |
| Completion | May 1, 2011 |
| First posted | May 26, 2006 |
| Last update posted | May 26, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: